<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<?xml-stylesheet type="text/css" href="css/atom.css"?>
<feed xmlns="http://www.w3.org/2005/Atom"><title type="html"><![CDATA[Chemicalinfo &amp; Chemlink &amp; Pharm-Chem Net]]></title><subtitle type="html"><![CDATA[Pharmaceutical Chemical Online Blog]]></subtitle><id>http://www.chemlink.org/blog/</id><link rel="alternate" type="text/html" href="http://www.chemlink.org/blog/"/><link rel="self" type="application/atom+xml" href="http://www.chemlink.org/blog/atom.xml"/><generator uri="http://www.rainbowsoft.org/" version="1.7 Laputa Build 70216">RainbowSoft Studio Z-Blog</generator><updated>2010-01-27T22:04:10+08:00</updated><entry><title type="html"><![CDATA[2009年国际一线药企重点研发产品时间表]]></title><author><name>admin</name><email>sales@chemlink.org</email></author><category term="" scheme="http://www.chemlink.org/blog/catalog.asp?cate=1" label="News"/><updated>2010-01-27T22:02:37+08:00</updated><published>2010-01-27T22:02:37+08:00</published><summary type="html"><![CDATA[2009年国际一线药企重点研发产品时间表2009/1/9/09:38 来源：医药网肿瘤：针对前列腺、肾脏等靶标 &nbsp;&nbsp;&nbsp; 据报道，目前制药业的研发线中有750只抗肿瘤药物。这其中的许多药物是不可能上市的，但下面的这些抗肿瘤药物不能让人忽视： &nbsp;&nbsp;&nbsp; 第一只是CougarBiotechnology公司用于治疗前列腺癌的口服药物阿比特龙（Abiraterone）。许多研究显示，前列腺癌能自身产生睾酮，而阿比特龙能抑制涉及到睾酮产生的酶CYP1...]]></summary><link rel="alternate" type="text/html" href="http://www.chemlink.org/blog/93."/><id>http://www.chemlink.org/blog/93.</id></entry><entry><title type="html"><![CDATA[治疗白血病的蛋白激酶抑制剂 Bosutinib]]></title><author><name>admin</name><email>sales@chemlink.org</email></author><category term="" scheme="http://www.chemlink.org/blog/catalog.asp?cate=1" label="News"/><updated>2010-01-26T10:05:51+08:00</updated><published>2010-01-26T10:05:51+08:00</published><summary type="html"><![CDATA[药学进展&nbsp;新药介绍 2008年第32卷第3 期第136页 136&nbsp;2008, Vol. 32, No. 3Progress&nbsp;in&nbsp;Pharmaceutical&nbsp;Sciences&nbsp;治疗白血病的蛋白激酶抑制剂 Bosutinib由美国惠氏制药公司(Wyeth Pharmaceuticals)研制的bosutinib(代号：SKI-606)是一种强效的蛋白激酶Src／Ab1双重抑制剂，既能抑制多种人肿瘤细胞中Src蛋白的自主磷酸化，也能抑制S...]]></summary><link rel="alternate" type="text/html" href="http://www.chemlink.org/blog/92."/><id>http://www.chemlink.org/blog/92.</id></entry><entry><title type="html"><![CDATA[新型糖尿病药物介绍-维格列汀(vildagliptin)]]></title><author><name>admin</name><email>sales@chemlink.org</email></author><category term="" scheme="http://www.chemlink.org/blog/catalog.asp?cate=1" label="News"/><updated>2010-01-14T15:54:39+08:00</updated><published>2010-01-14T15:54:39+08:00</published><summary type="html"><![CDATA[目前,虽说糖尿病还没有什么方法可以100%治愈,但是,在医务人员和科研人员的共同努力下,彻底攻克糖尿病有了新希望,目前又有了很多新招治疗糖尿病。我们来看一看&mdash;&mdash; 　　 　　肠促胰岛素类(Incretin) 　　 　　这是近年来极具潜力的一类降糖物质。2型糖尿病患者肠道分泌的这种激素十分缺乏,导致胰岛素不能正常有效地分泌,血糖持续升高。补充这种激素可以根本纠正这一异常紊乱。目前补充此类肠道激素的主要药物有:胰高糖素样多肽-1 (GLP-1) 类似物和二肽基肽酶-Ⅳ (DPP...]]></summary><link rel="alternate" type="text/html" href="http://www.chemlink.org/blog/91."/><id>http://www.chemlink.org/blog/91.</id></entry><entry><title type="html"><![CDATA[Cediranib Demonstrates Safe, Well Tolerated Antitumour Activity in Patients With Advanced Renal Cell Carcinoma]]></title><author><name>admin</name><email>sales@chemlink.org</email></author><category term="" scheme="http://www.chemlink.org/blog/catalog.asp?cate=1" label="News"/><updated>2009-12-18T15:30:13+08:00</updated><published>2009-12-18T15:30:13+08:00</published><summary type="html"><![CDATA[Cediranib Demonstrates Safe, Well Tolerated Antitumour Activity in Patients With Advanced Renal Cell Carcinoma: Presented at EMUC    By Chris Berrie        BARCELONA, Spain -- December 1, 2009 -- Cediranib is safe and well tolerated, and shows signif...]]></summary><link rel="alternate" type="text/html" href="http://www.chemlink.org/blog/90."/><id>http://www.chemlink.org/blog/90.</id></entry><entry><title type="html"><![CDATA[美国FDA的委员会同意Asteilas / Cardiome的心律失常药 Vernakalan]]></title><author><name>admin</name><email>sales@chemlink.org</email></author><category term="" scheme="http://www.chemlink.org/blog/catalog.asp?cate=1" label="News"/><updated>2009-04-13T14:33:42+08:00</updated><published>2009-04-13T14:33:42+08:00</published><summary type="html"><![CDATA[美国FDA的委员会同意Asteilas / Cardiome的心律失常药Vernakalan美国FDA心血管和肾脏药物顾问委员会以6:2同意Astellas/Cardiome Pharma新型抗心律失常药Kynapid(vernakalant盐酸注射液)(I)用于房颤(AF)的快速复律。(I)是混合的钾和钠通道阻断剂。两公司申请用于持续7天或以下的AF转为窦性心律的许可证。建议的剂量是开始以3mg／kg静脉滴注1O分钟，如在滴注完毕后15分钟内没有复律，则再给予2mg／kg，在1O分钟内滴注。疗...]]></summary><link rel="alternate" type="text/html" href="http://www.chemlink.org/blog/89."/><id>http://www.chemlink.org/blog/89.</id></entry><entry><title type="html"><![CDATA[GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic...]]></title><author><name>admin</name><email>sales@chemlink.org</email></author><category term="" scheme="http://www.chemlink.org/blog/catalog.asp?cate=2" label="Source"/><updated>2009-04-13T08:28:01+08:00</updated><published>2009-04-13T08:28:01+08:00</published><summary type="html"><![CDATA[GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment ofMetastatic Breast Cancer in Europe, USLONDON and PHILADELPHIA, April 1, /PRNewswire-FirstCall/ -- GlaxoSmithKline(NYSE: GSK) today announced the submission of two simultaneous reg...]]></summary><link rel="alternate" type="text/html" href="http://www.chemlink.org/blog/88."/><id>http://www.chemlink.org/blog/88.</id></entry><entry><title type="html"><![CDATA[临床研究证明: 达沙替尼(Dasatinib/Sprycel)治疗白血病是一种安全有效药物]]></title><author><name>admin</name><email>sales@chemlink.org</email></author><category term="" scheme="http://www.chemlink.org/blog/catalog.asp?cate=1" label="News"/><updated>2009-03-24T08:10:54+08:00</updated><published>2009-03-24T08:10:54+08:00</published><summary type="html"><![CDATA[达沙替尼（Dasatinib/Sprycel），用于已经治疗，包括甲磺酸伊马替尼（Imatinibmesylate/Gleevec）耐药或不能耐受的慢性骨髓性白血病所有病期（慢性期、加速期、淋巴系细胞急变期和髓细胞急变期）的成人患者。同 ...]]></summary><link rel="alternate" type="text/html" href="http://www.chemlink.org/blog/87."/><id>http://www.chemlink.org/blog/87.</id></entry><entry><title type="html"><![CDATA[Zilmax (Zilpaterol hydrochloride) Offers Extended Marketing Window For Cattle Feeders]]></title><author><name>admin</name><email>sales@chemlink.org</email></author><category term="" scheme="http://www.chemlink.org/blog/catalog.asp?cate=1" label="News"/><updated>2009-02-03T14:34:01+08:00</updated><published>2009-02-03T14:34:01+08:00</published><summary type="html"><![CDATA[Zilmax (Zilpaterol hydrochloride) Offers Extended Marketing Window For Cattle Feeders&nbsp;DE SOTO, Kan. (Feb. 2, 2009) &mdash; A few days of market fluctuations can have dramatic effects on a feedyard&rsquo;s bottom line, which means marketing flexi...]]></summary><link rel="alternate" type="text/html" href="http://www.chemlink.org/blog/86."/><id>http://www.chemlink.org/blog/86.</id></entry><entry><title type="html"><![CDATA[FDA Approves Gleevec (Imatinib mesylate) to Prevent Recurrence of Rare Gastrointestinal Cancer]]></title><author><name>admin</name><email>sales@chemlink.org</email></author><category term="" scheme="http://www.chemlink.org/blog/catalog.asp?cate=1" label="News"/><updated>2009-01-15T15:19:43+08:00</updated><published>2009-01-15T15:19:43+08:00</published><summary type="html"><![CDATA[FDA News                                    FOR IMMEDIATE RELEASE            December 19, 2008                                     Media Inquiries:             Karen Riley, 301-796-4674            Consumer Inquiries:             888-INFO-FDA         ...]]></summary><link rel="alternate" type="text/html" href="http://www.chemlink.org/blog/85."/><id>http://www.chemlink.org/blog/85.</id></entry><entry><title type="html"><![CDATA[FDA Approves Gleevec (Imatinib mesylate) for Gastrointestinal Stromal Tumor]]></title><author><name>admin</name><email>sales@chemlink.org</email></author><category term="" scheme="http://www.chemlink.org/blog/catalog.asp?cate=1" label="News"/><updated>2009-01-06T13:55:33+08:00</updated><published>2009-01-06T13:55:33+08:00</published><summary type="html"><![CDATA[                        FDA核准Gleevec(Imatinib mesylate)作为肠胃道基质肿瘤的治疗                            作者：Laurie Barclay, MD                             出处：WebMD 医学新闻                                        　　December 23, 2008 &mdash; 12月19日，美国食品药物管理局（FDA）核准i...]]></summary><link rel="alternate" type="text/html" href="http://www.chemlink.org/blog/83."/><id>http://www.chemlink.org/blog/83.</id></entry></feed>
